Hope on the horizon: Novel fungal treatments in development

Adriana M. Rauseo, Ariella Coler-Reilly, Lindsey Larson, Andrej Spec

Research output: Contribution to journalReview articlepeer-review

80 Scopus citations


The treatment of invasive fungal infections remains challenging due to limitations in currently available antifungal therapies including toxicity, interactions, restricted routes of administration, and drug resistance. This review focuses on novel therapies in clinical development, including drugs and a device. These drugs have novel mechanisms of action to overcome resistance, and some offer new formulations providing distinct advantages over current therapies to improve safety profiles and reduce interactions. Among agents that target the cell wall, 2 glucan synthesis inhibitors are discussed (rezafungin and ibrexafungerp), as well as fosmanogepix and nikkomycin Z. Agents that target the cell membrane include 3 fourth-generation azoles, oral encochleated amphotericin B, and aureobasidin A. Among agents with intracellular targets, we will review olorofim, VL-2397, T-2307, AR-12, and MGCD290. In addition, we will describe neurapheresis, a device used as adjunctive therapy for cryptococcosis. With a field full of novel treatments for fungal infections, the future looks promising.

Original languageEnglish
Article numberofaa016
JournalOpen Forum Infectious Diseases
Issue number2
StatePublished - Feb 1 2020


  • Antifungal drugs
  • Invasive fungal infections
  • Novel treatment
  • Review


Dive into the research topics of 'Hope on the horizon: Novel fungal treatments in development'. Together they form a unique fingerprint.

Cite this